100 related articles for article (PubMed ID: 27130844)
1. Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.
Zhu AX; Chen D; He W; Kanai M; Voi M; Chen LT; Daniele B; Furuse J; Kang YK; Poon RT; Vogel A; Chiang DY
J Hepatol; 2016 Aug; 65(2):296-304. PubMed ID: 27130844
[TBL] [Abstract][Full Text] [Related]
2. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
Rimassa L; Abbadessa G; Personeni N; Porta C; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; De Toni EN; Weiss A; Miles S; Gasbarrini A; Lencioni M; Lamar ME; Wang Y; Shuster D; Schwartz BE; Santoro A
Oncotarget; 2016 Nov; 7(45):72622-72633. PubMed ID: 27579536
[TBL] [Abstract][Full Text] [Related]
3. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma.
Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Hisamoto T; Yoshida Y; Abe M; Koga H; Toirimura T; Ueno T; Sata M
Oncol Rep; 2010 Jun; 23(6):1647-54. PubMed ID: 20428821
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
5. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
6. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
Helaly GF; Abou Shamaa LA
Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
Rimassa L; Kelley RK; Meyer T; Ryoo BY; Merle P; Park JW; Blanc JF; Lim HY; Tran A; Chan YW; McAdam P; Wang E; Cheng AL; El-Khoueiry AB; Abou-Alfa GK
Liver Cancer; 2022 Jan; 11(1):38-47. PubMed ID: 35222506
[TBL] [Abstract][Full Text] [Related]
8. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
10. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
11. Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma.
Yvamoto EY; Ferreira RF; Nogueira V; Pinhe MA; Tenani GD; Andrade JG; Baitello ME; Gregório ML; Fucuta PS; Silva RF; Souza DR; Silva RC
Genet Mol Res; 2015 Dec; 14(4):17453-62. PubMed ID: 26782388
[TBL] [Abstract][Full Text] [Related]
12. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
13. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma.
Lee SJ; Lee J; Sohn I; Mao M; Kai W; Park CK; Lim HY
Anticancer Res; 2013 Nov; 33(11):5179-86. PubMed ID: 24222167
[TBL] [Abstract][Full Text] [Related]
14. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
[TBL] [Abstract][Full Text] [Related]
15. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma.
Hu TH; Huang CC; Lin PR; Chang HW; Ger LP; Lin YW; Changchien CS; Lee CM; Tai MH
Cancer; 2003 Apr; 97(8):1929-40. PubMed ID: 12673720
[TBL] [Abstract][Full Text] [Related]
17. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
[TBL] [Abstract][Full Text] [Related]
18. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
19. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
20. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance.
Claudio PP; Russo G; Kumar CA; Minimo C; Farina A; Tutton S; Nuzzo G; Giuliante F; Angeloni G; Maria V; Vecchio FM; Campli CD; Giordano A
Clin Cancer Res; 2004 May; 10(10):3509-17. PubMed ID: 15161709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]